Q1 25 EPS
$-0.46
BEAT +4.11%
Est. $-0.48
Q1 25 Revenue
$7.7M
BEAT +69,017.91%
Est. $11,110
vs S&P Since Q1 25
+402.5%
BEATING MARKET
RLAY +434.7% vs S&P +32.2%
Market Reaction
Did RLAY Beat Earnings? Q1 2025 Results
Relay Therapeutics framed its Q1 2025 results as a story of deliberate strategic contraction, reporting a loss of $0.46 per share on revenue of $7.68 million as the clinical-stage biotech executed sweeping cost reductions designed to concentrate reso… Read more Relay Therapeutics framed its Q1 2025 results as a story of deliberate strategic contraction, reporting a loss of $0.46 per share on revenue of $7.68 million as the clinical-stage biotech executed sweeping cost reductions designed to concentrate resources on its most advanced programs. The $7.68 million in revenue, down from $10.01 million a year ago, reflected the completion of all performance obligations under the company's out-license agreement with Elevar Therapeutics for RLY-4008. The net loss narrowed to $77.06 million from $81.39 million in Q1 2024, aided by a decline in R&D spending to $73.81 million from $82.40 million following restructuring actions that cut the research run rate by roughly 80% and reduced headcount by approximately 70 people. With $710.36 million in cash and investments on hand, management said the company is funded into 2029, a runway expected to cover topline data from the Phase 3 ReDiscover-2 trial of lead asset RLY-2608 in metastatic breast cancer, with that trial initiation on track for mid-2025.
Key Takeaways
- • Completion of all performance obligations under Elevar Exclusive License Agreement drove Q1 2025 revenue
- • Strategic cost reductions including 80% reduction in research run rate spend and workforce reduction of approximately 70 people
- • Reduction in research-stage programs from four to one
RLAY YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
“2025 is a year of execution across a range of high value clinical programs. The ongoing changes to our cost base are designed to enable a full funding of key initiatives including generating topline data from the ReDiscover-2 trial and clinical proof-of-concept data in vascular malformations.”
— Sanjiv Patel, Q1 2025 Earnings Press Release
RLAY Earnings Trends
RLAY vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
RLAY EPS Trend
Earnings per share: estimate vs actual
RLAY Revenue Trend
Quarterly revenue: estimate vs actual
RLAY Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-0.36 | $-0.41 | -15.01% | $3.0M | -35.48% |
| Q4 25 BEAT FY | $-0.40 | $-0.32 | +19.17% | $7.0M | +61.41% |
| FY Full Year | — | $-1.61 | — | $15.4M | — |
| Q3 25 MISS | $-0.42 | $-0.43 | -2.75% | $0 | -100.00% |
| Q2 25 BEAT | $-0.44 | $-0.41 | +7.66% | $677,000 | +4,637.58% |
| Q1 25 BEAT | $-0.48 | $-0.46 | +4.11% | $7.7M | +69,017.91% |